Abstract: This specification discloses resorbable calcium phosphate-based bio-compound particles and the manufacturing method thereof. Through the manufacturing process control, collagen has sufficient time to reconstruct and forms a network structure, which then combines with calcium phosphate-based ceramic powders that are controlled to have diameters ≦5 &mgr;m so as to provide a bio-compound acceptable by humans and having a similar structure and constituents to the bony tissues. There is no need for a second operation when such material is used in medical practice and the bony tissues can undergo fast and effective bone-genesis.

Abstract: The present invention provides a novel process for producing a calcium phosphate cement or filler which hardens in a temperature dependent fashion in association with an endothermic reaction. In the reaction a limited amount of water is mixed with dry calcium phosphate precursors to produce a hydrated precursor paste. Hardening of the paste occurs rapidly at body temperature an is accompanied by the conversion of one or more of the reactants to poorly crystalline apatitic calcium phosphate. The hardened cements, fillers, growth matrices, orthopedic and delivery devices of the invention are rapidly resorbable and stimulate hard tissue growth and healing.

Abstract: The present invention provides a novel process for producing a calcium phosphate cement or filler which hardens in a temperature dependent fashion in association with an endothermic reaction. In the reaction a limited amount of water is mixed with dry calcium phosphate precursors to produce a hydrated precursor paste. Hardening of the paste occurs rapidly at body temperature an is accompanied by the conversion of one or more of the reactants to poorly crystalline apatitic calcium phosphate. The hardened cements, fillers, growth matrices, orthopedic and delivery devices of the invention are rapidly resorbable and stimulate hard tissue growth and healing.

Abstract: The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m2g−1. The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.

Abstract: The present invention relates to pharmaceutical combination preparations comprising a) single administration forms of a parathyroid hormone preparation (PTH) suitable for single dosage of the active substance in a maximum amount of 20 &mgr;g of PTH, and b) a calcium/phosphate preparation wherein the calcium and phosphate compounds may be present in separate administration forms or in an integrated administration form.

Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the calcium dissolves in the aqueous solution setting of the cellulose phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.

Abstract: A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

Abstract: The invention concerns a synergetic fungicide and/or bactericide composition comprising famoxadone and a phosphorous acid derivative; and a method for fighting, for cure or prevention, against phytopathogenic fungi and/or bacteria using such a composition.

Abstract: A composition for the induction of bone growth is disclosed. The composition includes a substrate, bone growth protein, and sources of calcium and phosphate. The composition is acidic which promotes high activity of the bone growth protein. The calcium and phosphate sources can be provided as an acidic calcium phosphate salt. Also disclosed are methods of the making the composition and methods of using it.

Abstract: Methods are provide for producing flowable compositions, e.g. pastes, that set into calcium phosphate products. In the subject methods, dry reactants that include a calcium source and a phosphate source are combined with a solution of a soluble silicate, e.g. sodium silicate, and the combined liquids and solids are mixed to produce the flowable composition. Also provided are the compositions themselves as well as kits for preparing the same. The subject methods and compositions produced thereby find use in a variety of applications, including the repair of hard tissue defects, e.g. bone defects.

Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.

Abstract: This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

Abstract: Hollow particles having a shell substantially composed of calcium-phosphate, methods for preparing the same, and methods of use are disclosed. The particles are obtained by differential immersion of silica-based, calcium and phosphate containing glass particles.

Abstract: The present invention relates to a novel pharmaceutical composition and process for preparing swallowable methylcellulose tablets that disintegrate rapidly and meet USP standards in 0.1N hydrochloric acid as well as water.

Abstract: A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention.

Abstract: A suspension or a particle-solvent mixture system, which contains microparticles of zinc-containing calcium phosphate with particular chemical composition, specifically, microparticles of sparingly soluble zinc-containing calcium phosphate, and a therapeutic agent for treating zinc deficiency are provided. Particularly, a suspension or particle-solvent mixture system is prepared by mixing microparticles of zinc-containing calcium phosphate consisting of from 0.6 ppm to 13% by weight of zinc, 33-57% by weight of P2O5, 10-65% by weight of CaO and 0-28% by weight of H2O with a water-miscible or water-immiscible solvent. Such a suspension or particle-solvent mixture system can be used as a therapeutic agent for treating zinc deficiency.

Abstract: Calcium composition having improved dissolution rate, which comprises granular agglomerates consisting of elementary granules of at least one calcium salt and at least one wetting agent, forming layers around and between the elementary granules in each agglomerate. The ratio of wetting agent to calcium salt is from 0.1 to 5%. The calcium salt may be a soluble one, chosen from among calcium lactate gluconate and calcium monophopshate, and has a solubility of at least 2 gr/100 ml of water. The wetting agent may be an edible one, chosen from among dioctyl sodium sulphosuccinate, propylene glycol lactostearate, propylene glycol and sodium lauryl sulphate. The size of the elementary granules of calcium salt is less than 50 &mgr;m, and preferably less than 30 &mgr;m.

Abstract: A method for preparing a hydroxyapatite composite is disclosed. This method comprises alternately soaking a matrix which has been made hydrophilic at least on its surface, in a calcium ion aqueous solution containing calcium ions and substantially free of phosphate ions and in a phosphate ion aqueous solution containing phosphate ions and substantially free of calcium ions to securely form hydroxyapatite at least on the surface of the matrix. Also disclosed is a biocompatible material composed of the hydroxyapatite composite obtained by the method.

Abstract: Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A shaped, inorganic body is formed in situ. Optional, but preferred additional thermal treatment of the shaped, inorganic body removes the organic substrate, leaving an inorganic body that faithfully mimics the porosity, shape, and other physical characteristics of the organic substrate. Inorganic substrates may also be used to good effect. Large varieties of shaped bodies can be prepared in accordance with other embodiments of the invention and such shapes find wide use in surgery, laboratory and industrial processes and otherwise. The invention also provides chemically and morphologically uniform powders, including those having uniformly small sizes.

Abstract: Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones.

Abstract: A process for providing nutrient material for banana and plantain plants, comprising providing a slow release implant containing a banana and plantain nutrient material and implanting the implant into banana or plantain plants whereby the nutrient is slowly released into the plant over a period of time.

Abstract: A hair growth formulation. The two basic main ingredients are castor oil and a special lemon extract. The special lemon extract is made from fresh lemon peel. The peel, including the bioflavonoids membrane, is blended with purified water until it is liquidified. Then the mixture is filtered through a sanitized cloth. Other ingredients that have been found helpful include: inositol, choline (from bitartate), niacinamide or nicotinic acid, manganese in chelated form, bioflavonoids, and folic acid. Finally perfume and sodium benzoate (as a preservative) can be added.

Abstract: Biomaterial, for example bioactive silicon, may be fabricated by anodizing a silicon wafer to produce a wafer having a porous silicon region. In vitro experiments have shown that certain types of porous silicon cause the deposition of apatite deposits both on the porous silicon and neighboring areas of bulk silicon when immersed in a simulated body fluid solution. This deposition of apatite provides an indication that porous silicon of appropriate form is bioactive, and therefore also biocompatible. A form of porous silicon is dissolved in the simulated body fluid solution and this is an indication of a resorbable biomaterial characteristic. In addition to porous silicon, certain types of polycrystalline silicon exhibit bioactive characteristics. Bioactive silicon may be used in the fabrication of biosensors for in vitro or in vivo applications. The bioactivity of the bioactive silicon may be controlled by the application of an electrical potential thereto.

Abstract: Synergistic fungicidal composition comprising propamocarb and a derivative of phosphorous acid; and process for the curative or preventative control of phytopathogenic fungi by use of such a composition.

Abstract: The present invention provides calcium phosphate-based (CaP) microcarriers and their use, for example, in cell culturing systems, chromatography, and implantable biomedical materials.

Abstract: Disclosed is a deodorizer composition comprising magnesium and calcium phosphate compounds, capable of effectively removing various malodorous components from the atmosphere.

Abstract: The invention is directed to a composition and method for correcting a dietary phytochemical deficiency, wherein the phytochemicals include sulphoraphane, naringen, hesperidin, narirutin, quercetin, &bgr;-carotene, lutein, lycopene, and isoflavones. The composition may also comprise additional vitamins and minerals.

Abstract: The invention deals with phosphate water solution with cold solidification capacity. Phosphate composition containing iron oxide solution in acid, water, advantages from the following properties; it contains orthophosphorus acid and in addition metal powder. Phosphate composition is ecologically pure product, non toxic, non cancerogenic, non-allergic. It has antimicrobial, antivirus and fungicidal properties. Phosphate composition can be applied within medicine: surgery, dermatology, dentistry, oncology, pharmacology and other branches. In agriculture use: as a means of curing plant diseases, within veterinary—as a means for preventive maintenance and curing of animal diseases, within construction—as an anticorrosive, fire-resistant, hydro-electric isolating covers, ceramic tiles, concretes, which protect against radiation, as well as for producing other composite materials.

Abstract: An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and/or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and/or lower alcohols.

Abstract: A food composition containing a food product, fish oil, and a fish oil stabilizing agent. The fish oil is a nonhydrogenated fish oil containing omega-3 long chain fatty acids that has been deodorized and refined for packaging. The stabilizing agent consists of the citrus flavonoid naringin that is derived from the pulp and peel of grapefruit. The stabilizing agent comprises between about 0.003 weight percent of the food composition to about 0.02 weight percent of the food composition. The stabilizing agent protects the fish oil from taste and odor degradation, and allows for long term storage of the food composition containing the fish oil.

Abstract: The invention refers to an aqueous solution for the parenteral nutrition of mammals consisting of: a) a pattern of amino acids calculated on the basis of 100 g/l of amino acids: Isoleucine 4.0-5.5 g/l Leucine 8.0-10.0 g/l Lysine 6.0-8.0 g/l Methionine 4.0-6.0 g/l Phenylalanine 4.0-6.0 g/l Threonine 4.0-6.0 g/l Tryptophane 1.0-2.0 g/l Valine 6.0-8.0 g/l Arginine 10.0-12.0 g/l Histidine 1.5-3.5 g/l Alanine 9.0-12.0 g/l Aminoacetic Acid (Glycine) 11.0-16.0 g/l Asparagine 0-1.0 g/l Aspartic Acid 5.5-8.0 g/l Acetylcysteine 0-2.5 g/l Glutamic Acid 6.0-10.0 g/l Ornithine 0-1.0 g/l Proline 4.0-6.0 g/l Serine 1.0-3.0 g/l Tyrosine* 01.-0.5 g/l *as Acetyltyrosine 0-2.0 g/l Taurine 0-4.

Abstract: Uniformly sized and shaped particles of metal salts are provided comprised of one or more metal cations in combination with one or more simple oxoacid anions and a general method for the controlled precipitation of said metal salts from aqueous solutions. The methods proceed via the in situ homogeneous production of simple or complex oxoacid anions in which one or more of the nonmetallic elements e.g. Group 5B and 6B (chalcogenides), and 7B (halides) comprising the first oxoacid anion undergo oxidation to generate the precipitant anionic species along with concurrent reduction of the nonmetallic element of a second, dissimilar oxoacid anion. The oxoacid anions are initially present in solution with one or more metal cations known to form insoluble salts with the precipitant anion.

Abstract: This invention relates, generally, to nutritional supplements which contain bioactive glass. These supplements are useful in both veterinary and human contexts. The compositions of the subject invention can be used to achieve a number of advantageous results including: enhancing the growth rates of young animals, osteogenic stimulation, strengthening the skeletal structure, and treating osteoporosis.

Abstract: A method for restoration of the circadian rhythm of parathyroid hormone (PTH) serum levels in a subject having osteoporosis, so as to restore a circadian rhythm of PTH levels which is similar to that existing in normal subjects is disclosed by administering a single daily dose of a composition consisting essentially of an effective amount of phosphate in the evening or at night, whereby the composition causes a circadian rhythm of PTH levels which peaks during the night, whereby the circadian rhythm of PTH levels is restored to that which is similar to that existing in normal subjects, thereby treating osteoporosis.

Abstract: An anticorrosive and antifouling additive for paints, which is effective to protect structures such as steel ships and pipes from rust, and prevent the adhesion of marine organisms and algae to the structures used in seawater without adversely affecting the marine environment, and a paint containing the same additive are provided. The additive comprises 70 to 94% by weight of at least one selected from the group consisting of bastnasite, monazite and Chinese complex mineral, 3% by weight or more of tourmaline, and 3% by weight or more of zircon, with respect to the total amount of the additive. The additive emits a required amount of negative ions to achieve the effect of preventing the adhesion of marine organisms and algae and prevents the occurrence of rust. In practical use, the additive can be added to a conventional paint in an amount of 8 to 15% with respect to paint weight.

Abstract: The present invention provides calcium phosphate-based (CaP) microcarriers and their use, for example, in cell culturing systems, chromatography, and implantable biomedical materials.

Abstract: A method for treating a bone defect is provided by identifying a bone site suitable for receiving an implant; and introducing a strongly resorbable, poorly crystalline apatitic calcium phosphate at the implant site, whereby bone is formed at the implant site. A bone defect may be treated by identifying a bone site suitable for receiving an implant; and introducing a hydrated precursor to a strongly resorbable, poorly crystalline apatitic calcium phosphate at the implant site, whereby the hydrated precursor is converted in vivo to a poorly crystalline apatitic calcium phosphate and whereby bone is formed at the implant site. The implant site may be a variety of sites, such as a tooth socket, non-union bone, bone prosthesis, an osteoporatic bone, an intervertebral space, an alveolar ridge or a bone fracture.

Abstract: The present invention provides a composition of matter which has been demonstrated to be a very effective treatment for acne, seborrheic dermatitis and related skin diseases when applied to and contacted with affected skin areas, while avoiding the disadvantages and complications attendant to more established treatments. The composition comprises a synthetic mixture of salts which, when dissolved in a solvent such as water, is ionically composed primarily of a mixture of sodium and magnesium cations and chloride and sulfate anions, and which is preferably free of added zinc. More specifically, the salt mixture according to the present invention comprises the following range of composition in grams/kilogram of salt mixture in the ionic state, the balance being water of hydration: I.

Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca-P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.

Abstract: A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention.

Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca—P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.

Abstract: The present invention provides a novel process for converting a standard inert amorphous calcium phosphate precipitate into highly reactive amorphous solids. The amorphous solids can be used to react with other calcium phosphate solids to form a poorly-crystalline synthetic hydroxyapatite that provides both bioactivity and structural integrity. This novel amorphous material can be reacted with other calcium phosphates at or below 37° C. to form a bone-like material consisting of poorly crystalline hydroxyapatite.

Abstract: The present invention provides calcium phosphate-based (CAP) microcarriers and microspheres and their use in cell culturing systems, chromatography and implantable biomedical materials.

Abstract: The invention relates to biocement pastes based on tricalcium phosphate and materials which are suitable for preventing or reducing the tendencies of the settable pastes to disintegrate and for improving their cohesion properties, with the result that improved processing of said pastes in the preparation of synthetic bone cements is ensured.

Abstract: An objective of the present invention is to provide compositions for supplying minerals to patients who underwent gastrectomy to thereby treat or prevent postgastrectomic syndrome. The composition for postgastrectomic mineral supply according to the present invention comprises an indigestible oligosaccharide and/or an indigestible sugar alcohol and a mineral.

Abstract: Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelates, and the metal amino acid chelate growth facilitator, promoter and enhancer prepared by the process.

Abstract: Compositions for the treatment and prevention of migraine or stress headaches wherein there is supplied a combination of potassium, magnesium and pyridoxine optionally in association with other nutrients and/or simple analgesics.

Abstract: Synergistic fungicidal composition comprising a compound analogous to strobilurin of formula (I): ##STR1## in which: A is the nitrogen atom or the --CH group,B is the --OCH.sub.2 -- or --CH.sub.2 O-- or CH(CH.sub.3)--O--N.dbd.CH-- or --CH.dbd.N--O--CH(CH.sub.3)-- group or the group ##STR2## R.sub.1 is an alkyl group containing 1 to 4 carbon atoms, R.sub.2 is --OCH.sub.3 or --NHCH.sub.3,X is a halogen atom, the cyano group or an alkyl or haloalkyl group containing 1 to 4 carbon atoms,n is equal to 1 or 2, with, when n is equal to 2, the possibility of having different X groups,and at least one fungicidal compound B, anda process for the curative or preventive control of phytopathogenic fungi using the composition.

Abstract: This invention encompasses porous, nanocrystalline, biomimetic calcium phosphate coatings of the order of 2-30 microns that can be grown on metal implants. The chemical surface treatments and methods for making the calcium phosphate coatings are disclosed. Post treatment with dilute hydrogels such as phema reinforce the inorganic structure and enhance the mechanical strength of the coatings. Methods are also disclosed for adsorbing or covalently attaching growth factor proteins to derivatives of the hydrogel coated calcium phosphate coatings. Such hydrogel reinforced calcium phosphate coatings show equivalent bone tissue growth as the currently used implants and are easily resorbed. This property in combination with the immobilized growth factors is expected to enhance the process of osseointegration of the disclosed coatings.

Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer unbound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer/micro-carrier.